Tramiprosate
Tramiprosate (also known as homotaurine) is a synthetic amino acid derivative that is commonly used in the treatment of Alzheimer's disease. It is a glycosaminoglycan mimetic which is believed to interfere with the aggregation of amyloid beta peptides in the brain, a key pathological feature of Alzheimer's disease.
History[edit | edit source]
Tramiprosate was originally developed by Neurochem Inc., a biopharmaceutical company based in Canada. The drug was initially investigated for its potential in treating amyloidosis, a group of diseases characterized by abnormal accumulation of proteins in various tissues of the body. However, the focus of research shifted to Alzheimer's disease after promising results were observed in preclinical studies.
Mechanism of Action[edit | edit source]
Tramiprosate is believed to work by binding to soluble amyloid beta peptides in the brain. This binding prevents the peptides from aggregating into insoluble plaques, which are a hallmark of Alzheimer's disease. By preventing plaque formation, tramiprosate may help to slow the progression of the disease.
Clinical Trials[edit | edit source]
Several clinical trials have been conducted to evaluate the efficacy and safety of tramiprosate in patients with Alzheimer's disease. The results of these trials have been mixed, with some studies showing a benefit and others showing no significant effect. Further research is needed to fully understand the potential benefits and risks of this treatment.
Side Effects[edit | edit source]
Common side effects of tramiprosate include nausea, vomiting, and weight loss. In rare cases, it can cause more serious side effects such as liver damage or kidney damage. Patients should be closely monitored for these potential complications while taking tramiprosate.
Future Directions[edit | edit source]
Despite the mixed results of clinical trials, research into the potential benefits of tramiprosate for Alzheimer's disease continues. Future studies may focus on identifying which patients are most likely to benefit from this treatment, or on developing new formulations of the drug that may be more effective or have fewer side effects.
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
